SL32A HINDI BIOCON | Share | Stock | Price | Market | News | Analysis | Review 13May21

BIO-TECHNOLOGY PIONEER – STRONG INCOME STREAMS CONSISTENT PERFORMANCE , SERVING GLOBAL GIANTS BIOSIMILARS – QUALITY SIMILAR , PRICE INEXPENSIVE PARTNERSHIP WITH GLOBAL LEADERS – MYLON AND SANDOZ BIOCON BIOLOGICS – VALUE UNLOCK POTENTIAL ON LISTING REVENUE LEADERSHIP OF BIOSIMILARS MAJOR PROFIT CONTRIBUTION FROM SYNGENE MEAGRE REVENUE GROWTH, BIG SLIDE IN PROFITS IMPRESSIVE REVENUE GROWTH , STEEP EROSION IN PROFITS MOMENTUM IN REVENUE, MINOR FALL IN PROFITS US TECHNOLOGY COMPANY INTO CANCER THERAPIES CHANGED INTO ASSOCIATE – ENABLING LOCAL FUNDING Rs. 220 Cr.

OF DILUTION GAIN & LICENSE FEE TO BIOCON NORMAL REVENUE – OTHER INCOME HALTS FALL IN PROFITS FALLING PBT – LOWEST TTM PBT % IN DEC – 20 QUICK AND ON-TIME MARKET RESPONSE ALWAYS UNDER MARKET WATCH RETRACEMENT AWAITING PERFORMANCE TRIGGER RSI IN OVERSOLD ZONE – PRICE CANDLE POSITIVE DAILY CHART HEIKIN ASHI – CHANGE OVER MOVES POSITIVE THREE MONTHS PRICE ACTION UNI-DIRECTIONAL ONE MONTH PRICE ACTION SIGNALS LIKELY REVERSAL FIRM STEPS OF THE PIONEER INTO FUTURE LEADERSHIP FDA VISIT & GREEN SIGNAL – LIKELY REAL GAME CHANGER STOCK LEARNING SIMPLIFIED – PLAY LIST AT INFO CARD

test attribution text

Add Comment